Sigilon
161 First Street
Suite 2C
Cambridge
Massachusetts
02142
U.S.A.
Phone:
617-336-7540
Fax:
n/a
|
Sigilon Therapeutics was founded and created by Flagship Pioneering. Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials, developed at the Massachusetts Institute of Technology (MIT), that can shield implanted cells from immune attack. Treatments based on Sigilon Therapeutics' technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.
YEAR FOUNDED:
June 2017
LEADERSHIP:
Scientific Founders: Bob Langer and Daniel Anderson
CEO: Paul Wotton
CTO: David Peritt, Ph.D.
CBO: James D. Watson
CAREER:
Please click here for Sigilon Therapeutics' job opportunities.
TECHNOLOGY
Please click here for Sigilon Therapeutics technology.
PIPELINE:
Please click here for Sigilon Therapeuticss pipeline.
Email:
info@sigilon.com
Ownership:
Private
Web Site:
Sigilon
Employees:
Symbol:
|